Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Int J Pharm. 2020 Jun 30;584:119403. doi: 10.1016/j.ijpharm.2020.119403. Epub 2020 May 5.
Recently, the main goal of many allergy epicutaneous immunotherapy (EPIT) studies is to enhance the allergen delivery through the intact skin. Therefore, applying new strategies for tackling this issue are inevitable. For this purpose, ten groups of Che a 2-sensitized BALB/c mice were epicutaneously treated for a 6-week period with the rChe a 2-GNPs-Aptamer, rChe a 2-GNPs-Aptamer + skin-penetrating peptides (SPPs), rChe a 2-GNPs, rChe a 2, GNPs, and PBS. Afterward, the serum IgE and IFN-γ, TGF-β, IL-10, IL-4, IL-17a cytokine production, NALF analysis, and lung/nasal histological examinations were performed. The present study results demonstrate that, EPIT in aptamer treated groups had a significant increase of IFN-γ, TGF-β, and IL-10 concentrations and a significant decrease of IgE, IL-4, and IL-17a concentrations as well as NALF infiltrated immune cell count compared to the non-targeted ones. In addition, SPPs led to more significant improvement of immunoregulatory parameters, especially IL-10 cytokine. Accordingly, the targeted-GNPs with DC-specific aptamers could act as an efficient approach for the improvement of EPIT efficacy compared to the free allergen. Moreover, the application of SPPs might be considered as a useful tool in achieving a successful EPIT with lower doses of allergen at a shorter duration of the treatment.
最近,许多过敏症经皮免疫治疗(EPIT)研究的主要目标是通过完整的皮肤增强过敏原的传递。因此,应用新的策略来解决这个问题是不可避免的。为此,将 10 组 Che a 2 致敏的 BALB/c 小鼠进行经皮治疗 6 周,用 rChe a 2-GNPs-Aptamer、rChe a 2-GNPs-Aptamer+皮肤穿透肽(SPP)、rChe a 2-GNPs、rChe a 2、GNPs 和 PBS 处理。之后,检测血清 IgE 和 IFN-γ、TGF-β、IL-10、IL-4、IL-17a 细胞因子的产生、NALF 分析和肺/鼻组织学检查。本研究结果表明,与非靶向组相比,在适配体处理组中,EPIT 导致 IFN-γ、TGF-β 和 IL-10 浓度显著增加,IgE、IL-4 和 IL-17a 浓度以及 NALF 浸润免疫细胞计数显著降低。此外,SPP 导致免疫调节参数的显著改善,特别是 IL-10 细胞因子。因此,与游离过敏原相比,带 DC 特异性适配体的靶向-GNPs 可作为提高 EPIT 疗效的有效方法。此外,应用 SPP 可能被认为是一种有用的工具,可在更短的治疗时间内用更低剂量的过敏原实现成功的 EPIT。